Where to Find More Information on This Undercovered Stock
For those looking for more information on DRTX, one of the best articles I've come across was one by Marcus Aarino posted on Mar 26, 2013 at Seeking Alpa. Points he made in this article were that insiders owned 70% of the company and there had been seven insider buy transactions and no insider sell transactions since July 20 and that four analysts had buy ratings with an average price target of $15.50. Marcus said, "The next two major catalysts for the stock will be the NDA submission with the FDA in mid-year and the MAA with the EMA at year-end 2013. If dalbavancin will be approved early next year, I believe the stock could reach the $15.50 price target." Another thing to take note of is the low float of 9.88M shares vs total shares of 26.63M shown in the Key Statistics at Yahoo Finance. I believe these figures don't include the recent secondary sale of 8.22M shares of stock on April 13, 2013 so the float now is probably around 18.1M with 34.85M total shares.